Immunogenicity and safety of a 12-valent pneumococcal conjugate vaccine in infants aged 6-10 weeks: a randomized double-blind active-controlled trial.

Journal: Clinical and experimental pediatrics
Published Date: Dec 6, 2019

Abstract

BACKGROUND: Pneumococcal diseases among children aged <5 years worldwide are associated with high annual mortality rates.

Authors

  • Jonghoon Shin
    SK bioscience, Seonam-si, Republic of Korea.
  • Jamaree Teeratakulpisarn
    Department of Pediatrics, Khon Kaen University, Khon Kaen, Thailand.
  • Thanyawee Puthanakit
    Department of Pediatrics and Center of Excellence in Pediatric Infectious Diseases and Vaccine Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Tuangtip Theerawit
    Department of Pediatrics and Center of Excellence in Pediatric Infectious Diseases and Vaccine Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Ji Hwa Ryu
    SK bioscience, Seonam-si, Republic of Korea.
  • Jinhwan Shin
    SK bioscience, Seonam-si, Republic of Korea.
  • Seulgi Lee
    SK bioscience, Seonam-si, Republic of Korea.
  • Hayoung Lee
    SK bioscience, Seonam-si, Republic of Korea.
  • Kyungjun An
    SK bioscience, Seonam-si, Republic of Korea.
  • Hun Kim
    SK bioscience, Seonam-si, Republic of Korea.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals